Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms

This article was originally published in The Pink Sheet Daily

Executive Summary

On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.
Advertisement

Related Content

Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Strong Phase III Data Have Linaclotide On Track For Filing In 2011
Daxas REMS May Be Key To Approval After "Complete Response" Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS071705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel